New surgical technique aims to improve outcomes for Right-Sided colon cancer
NCT ID NCT07207317
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a new type of laparoscopic surgery called LIRRH for people with right-sided colon cancer. The goal is to see if it leads to better long-term survival and fewer short-term problems like diarrhea or bowel blockage compared to the standard surgery. About 120 adults aged 18-75 with early-stage cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Laparoscopic ileocecal reconstruction right hemicolectomy (LIRRH) surgery
- What this could lead to
- If successful, this surgical technique could improve long-term survival and reduce post-surgery complications like diarrhea and bowel blockage for people with right-sided colon cancer.
- What could go wrong
- This is a relatively small, early-stage trial (120 participants) comparing two surgical methods. The new technique may not prove better than the standard approach, and surgical risks such as infection or bleeding still apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-75 years * ASA physical status ≤ III * Endoscopy and biopsy-proven colon adenocarcinoma * Contrast-enhanced abdominal CT showing primary tumor located in the ascending colon or proximal transverse colon (proximal one-third) * Pre-operative clinical stage: TanyNanyM0 * Able to understand the study protocol, willing to participate, and provide written informed consent Exclusion Criteria: * History of hypertensive crisis or hypertensive encephalopathy. * Severe cardiopulmonary insufficiency or any other contraindication to surgery. * Uncorrectable electrolyte disturbances (e.g., potassium, calcium, magnesium). * Evidence of significant bleeding diathesis or high hemorrhagic risk: * Prior intracranial or intraspinal hemorrhage. * Tumor invading major vessels with obvious bleeding risk. * Thrombotic or embolic event within 6 months before study treatment, or significant vascular disease (e.g., surgical-repair aortic aneurysm). * Clinically relevant hemoptysis or tumor bleeding of any cause within 1 month before screening. * Therapeutic-dose anticoagulation within 2 weeks before study treatment (except low-molecular-weight heparin). * Antiplatelet therapy within 10 days before study treatment (e.g., aspirin \> 325 mg/day, clopidogrel \> 75 mg/day, dipyridamole, ticlopidine, cilostazol). * Active tuberculosis. * Any active autoimmune disease or history of autoimmune disease with expected recurrence (including but not limited to SLE, RA, autoimmune hepatitis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyper- or hypothyroidism, asthma requiring bronchodilators). * Pre-operative evidence of synchronous multiple primary colorectal cancers or other conditions requiring additional bowel resection. * Pre-operative imaging or intra-operative findings showing: * Tumor infiltration into adjacent organs requiring multi-visceral resection; * Distant metastasis; * Unresectable (unable to achieve R0) disease. * Other malignancies within the past 5 years, or familial adenomatous polyposis; except cured carcinoma in situ of the cervix, basal-cell carcinoma, papillary thyroid carcinoma, or cutaneous squamous-cell carcinoma. * Intestinal obstruction, perforation, or bleeding requiring emergency surgery. * Patient unsuitable or unable to tolerate laparoscopic surgery. * Pregnant or lactating women. * History of psychiatric disorders precluding compliance. * Prior neoadjuvant therapy. * Multidisciplinary team (MDT) decision that the patient is not appropriate for the study. * Patient unable to understand the study conditions/objectives and refuses to give informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ascending colon cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.